These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 23232038)

  • 21. 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD.
    van Noord JA; Smeets JJ; Drenth BM; Rascher J; Pivovarova A; Hamilton AL; Cornelissen PJ
    Pulm Pharmacol Ther; 2011 Dec; 24(6):666-72. PubMed ID: 21839850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
    Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
    Maleki-Yazdi MR; Kaelin T; Richard N; Zvarich M; Church A
    Respir Med; 2014 Dec; 108(12):1752-60. PubMed ID: 25458157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.
    Hu C; Jia J; Dong K; Luo L; Wu K; Mehta R; Peng J; Ren Y; Gross A; Yu H
    PLoS One; 2015; 10(3):e0121264. PubMed ID: 25816315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects.
    Nakahara N; Wakamatsu A; Kempsford R; Allen A; Yamada M; Nohda S; Hirama T
    Int J Clin Pharmacol Ther; 2013 Aug; 51(8):660-71. PubMed ID: 23735179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
    Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C
    Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
    Bhatt SP; Dransfield MT; Cockcroft JR; Wang-Jairaj J; Midwinter DA; Rubin DB; Scott-Wilson CA; Crim C
    Int J Chron Obstruct Pulmon Dis; 2017; 12():351-365. PubMed ID: 28176907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
    Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
    Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
    Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.
    Crim C; Calverley PMA; Anderson JA; Holmes AP; Kilbride S; Martinez FJ; Brook RD; Newby DE; Yates JC; Celli BR; Vestbo J;
    Respir Med; 2017 Oct; 131():27-34. PubMed ID: 28947039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience.
    Albertson TE; Richards JR; Zeki AA
    Ther Adv Respir Dis; 2016 Feb; 10(1):43-56. PubMed ID: 26668137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial.
    Adachi M; Goldfrad C; Jacques L; Nishimura Y
    Respir Med; 2016 Nov; 120():78-86. PubMed ID: 27817819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial.
    Busse WW; O'Byrne PM; Bleecker ER; Lötvall J; Woodcock A; Andersen L; Hicks W; Crawford J; Jacques L; Apoux L; Bateman ED
    Thorax; 2013 Jun; 68(6):513-20. PubMed ID: 23440247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ▼Relvar Ellipta for COPD.
    Drug Ther Bull; 2014 Jun; 52(6):66-9. PubMed ID: 24904005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.
    McKeage K
    Drugs; 2014 Sep; 74(13):1509-22. PubMed ID: 25074268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
    Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
    Kerwin E; Ferguson GT; Sanjar S; Goodin T; Yadao A; Fogel R; Maitra S; Sen B; Ayers T; Banerji D
    Lung; 2017 Dec; 195(6):739-747. PubMed ID: 28993871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study.
    Mehta R; Kelleher D; Preece A; Hughes S; Crater G
    Int J Chron Obstruct Pulmon Dis; 2013; 8():159-67. PubMed ID: 23569370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol.
    Malerba M; Morjaria JB; Radaeli A
    Int J Chron Obstruct Pulmon Dis; 2014; 9():687-95. PubMed ID: 25061288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.